Manufacturing

Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.

The viscosity of oily emulsions can reduce filter capacity and bacterial retention.

Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.

The nimbleness of biotechs makes them well suited to implementing QbD. Here's how to get started.

Key considerations for defining your overall control strategy.

Suppliers, manufacturers, and governments must work together to plan how best to develop and deploy disposable systems for emergency response.

Do we really have to choose between saving money and saving time?

A case study compares capital costs, operating expenses, and NPV for a new MAb plant.

A case study assesses freezing time and physical robustness under stress.

Single-use connections can help drug manufacturers maximize efficiency in every step of the manufacturing process.

Many factors must be considered when choosing a sterile connector for a given process.

Process performance was comparable across all scales, and fiber optic sensors appeared interchangeable with conventional probes.

Genentech's evaluation of single-use technologies for bulk freeze-thaw, storage, and transportation.

An enterprise-wide quality management initiative is required to maintain supplier quality without sacrificing bottom-line objectives.

The future of therapeutic MAbs lies in the development of economically feasible downstream processes.

New techniques can overcome bottlenecks in existing facilities.

A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.

The industry and government must collaborate to develop robust technologies and quicker, more flexible manufacturing approaches for vaccine development.

New technologies such as virus-like particles are promising weapons in the battle against pandemic influenza.

Membrane-based TFF technology can ease scale-up and provide a higher recovery percentage compared to conventional purification methods.

Automated in-line dilution can help solve capacity, financial, and quality concerns that biopharmaceutical manufacturing plants may be facing.

It is now possible to combine antigens with specific adjuvant systems to create more effective vaccines.

Small changes can have a big effect further downstream in your manufacturing processes.

Needle-free vaccine delivery platforms can solve the problems of stockpiling, cold-chain management, and pandemic preparedness.